Multifunctional and Multimodal Theranostics: Manipulating Material Properties for Advanced Diagnostics. The utilisation of polymers in nanomedicine requires a bottom-up approach, where the fundamental chemistry is well-established and understood before it enables an application. This project develops branched polymers as new nanomaterials for theranostics; imaging modalities that “switch-on” when miRNA is released will quantify how much nanomaterial gets to a specific site, while a built-in sens ....Multifunctional and Multimodal Theranostics: Manipulating Material Properties for Advanced Diagnostics. The utilisation of polymers in nanomedicine requires a bottom-up approach, where the fundamental chemistry is well-established and understood before it enables an application. This project develops branched polymers as new nanomaterials for theranostics; imaging modalities that “switch-on” when miRNA is released will quantify how much nanomaterial gets to a specific site, while a built-in sensor based on physical changes in the nanomaterial will measure the onset and progression of necrosis. The aim is to develop a fundamental understanding of how polymer architecture and functionality can be utilised to drive device performance, providing a platform to probe new technology and methodologies for development of next generation theranostics.Read moreRead less
Multimodal polymeric nanocarriers designed for the controlled and site specific delivery of nitric oxide. Nitric oxide (NO) plays a key role in the development of different diseases. The chronic deficiency of NO results in severe problems such as cardiovascular diseases, liver fibrosis, diabetes, cancer, Alzheimer’s diseases, etc. This project will describe a new method to deliver specifically nitric oxide using macromolecules.
Smart magnetic resonance imaging (MRI) contrast agents: from early detection to assessment of drug delivery mechanisms. 'Smart' contrast agents will be developed for enhancing the performance of magnetic resonance imaging (MRI) of diseases such as cancer by designing them to be triggered by biochemical markers for disease. This has the potential to aid in early detection which can lead to lower mortality rates and consequently a lower burden on the health system.
Traceable theranostics: tools for visualising drug delivery and therapeutic benefit in vivo. Forty-three thousand people died from cancer in Australia in 2010. The aim of this project is to advance the concept of 'personalised-therapy' through the development of novel imaging devices based on polymers that can 'switch-on' and deliver drugs in specific tissues, allowing more sensitive and earlier detection and monitoring of diseases and therapies.